Back to today’s briefing

Story perspectives

Exelixis Stock Soars 7.4% on Promising Cancer Drug Results

6/24/2025

24 3

Summary

Story summary

Exelixis (EXEL) shares surged 7.4% following promising study results for zanzalintinib, a groundbreaking cancer treatment for difficult colon cancer cases. When paired with Roche's Tecentriq, the drug demonstrated enhanced survival rates over regorafenib. Analysts are optimistic, forecasting zanzalintinib could rake in $5 billion in U.S. sales by 2033.

1 of 1

Story summary

Exelixis (EXEL) shares surged 7.4% following promising study results for zanzalintinib, a groundbreaking cancer treatment for difficult colon cancer cases. When paired with Roche's Tecentriq, the drug demonstrated enhanced survival rates over regorafenib. Analysts are optimistic, forecasting zanzalintinib could rake in $5 billion in U.S. sales by 2033.